Release form. Tablets, coated, with the modified release.
Farmakoterapevtichesky group. The selection antagonist α1-адренорецепторов.
Code of automatic telephone exchange C02C And 04.
Effect of the medicine. Pharmacodynamics. Doksazozin is the selection antagonist α1-адренорецепторов long action. It reduces a blood pressure at the expense of the prevention of reduction of unstriated muscles of walls of peripheral vessels thanks to what decrease in the general peripheric resistance results.
Resistance to a doksazozin does not develop even after prolonged treatment.
Doksazozin reduces the level of the general cholesterol, cholesterol of lipoproteins low density, triglycerides and stimulates increase of level of cholesterol of lipoproteins of high density. Doksazozin can be appointed the patient to insulin-dependent diabetes as he shows neutral or even positive action on a metabolism of glucose of blood and sensitivity to insulin. Doksazozin suppresses aggregation of thrombocytes a little. At long-term treatment doksazozin reduces the mass of a left ventricle. Doksazazin is safe for patients with a renal failure, chronic obstructive diseases of the lungs sick on a peripheral arterial angiopatiya and gout.
After reception of a single dose of a doksazozin the effect proceeds 24 hours. The stable effect lowering of blood pressure is observed in several weeks of regular reception.
Doksazozin prevents reductions of unstriated muscles of upper part of an urethra and muscles of a prostate which surround and squeeze an urethra. Owing to relaxation of muscles it is facilitated urinations that promotes elimination of unpleasant symptoms which are observed at a benign hyperplasia of a prostate. Elimination of symptoms is observed after two weeks of treatment, at further treatment of display of a disease considerably decrease. Compared with usual tablets of a doksazozin of a tablet with the modified release have better than comparison of efficiency and safety.
Drug almost does not influence normal arterial pressure.
At treatment sexual dysfunction can decrease.
Pharmacokinetics. Kamiren XL, tablets with the modified release, are well soaked up. The maximum concentration of a doksazozin in a blood plasma is gradually reached in 8–9 hours after peroral use. In blood doksazozin almost completely contacts proteins of plasma. Its metabolic decomposition results in a liver, and he is brought together with a stake generally in the form of metabolites. Less than 5% of the entered dose are removed with urine in an invariable look. The elimination half-life makes 22 hours. At people of advanced age and patients with a renal failure pharmacokinetic properties of a doksazozin almost do not differ from properties in an organism of young people with normal function of kidneys.
At patients with a liver failure removal of a doksazozin is slowed down and considerably concentration in plasma and the size AUC increases (the area under a curve of dependence of concentration from time).
Indications to use. Arterial hypertension, prostate hyperplasia.
Way of use and dose. Kamiren XL, tablets with the modified release, it is necessary to swallow whole, washing down the liquid determined by quantity. Drug can be used to, during the period or after food.
Hypertensia and benign hyperplasia of a prostate
It is necessary to begin treatments with Kamiren ordinary, the initial dose makes 1 mg a day with gradual increase in a dose of drug in 1 – 2 weeks and to pass to Kamiren XL'S use, tablets with the modified release.
Usual dose of Kamiren XL is 1 tablet (4 mg) a day. Influence of drug is found in the first day, but the full effect is reached in 4 weeks of treatment. The daily dose of 4 mg is effective for most of patients. At inadequate treatment in 4 weeks and on condition of normal drug transferring by the patient it is possible to appoint higher dose. Maximum the dose - 2 tablets (8 mg) is recommended once a day.
For people of advanced age and for patients with a renal failure it is not necessary to reduce a dose.
If the patient having missed reception of a dose, then she does not need to be filled up, and the following pill should be taken in usual time.
Side effect. In an initiation of treatment at increase of a dose in some patients orthostatic reactions are possible that they are found in lowering of arterial pressure, dizziness and even unconsciousness when changing position of a body. These effects are temporary. Kamiren XL in the form of tablets with the modified release of active ingredient provides uniform concentration of a doksazozin in a blood plasma without the expressed peak therefore the risk of emergence orthostatic than hypotonia or some other side effects is lower compared with risk when using ordinary tablets. These phenomena, as a rule, disappear spontaneously, but at emergence of long-term or strong side effects it is recommended to reduce a dose or to cancel drug.
To side effects of a doksazozin (> 1%) belong provided below:
Vegetative nervous system: dryness in a mouth.
Organism in general: an adynamy, a dorsodynia, a stethalgia, symptoms that remind flu.
Liver and gall bladder: pathological indicators of function of a liver, cholestasia, hepatitis, jaundice.
Bones and muscles: joint pain, muscular spasms, weakness of muscles.
Psychiatric disturbances: the excited state, a depression, excessive intensity, sleeplessness, anorexia.
System of breath: to deterioration in a bronchospasm, dispnoe, cough, nasal bleeding.
Skin: hair loss, skin rash.
Touch bodies: a sight illegibility, a ring in ears.
Urinary tract: hamaturia, disturbances of an urination (dysuria, frequent urinations, nokturiya), impotence, priapism.
Contraindications. Drug should not be used at hypersensitivity to a doksazozin or other derivatives of quinazoline or to any substance that is a part of this drug.
Overdose. Overdose of a doksazozin can entail, first of all, hypotension, dizziness and a faint. For most of patients the dose decline of drug or temporary a suspension of treatment by it is sufficient.
After reception of too high dose hypotension can be observed.
The patient needs to be transferred to horizontal position, to hang the head, and to raise legs a little. It is not recommended to cause vomiting. It is necessary to carry out other actions for removal in a drug digestive tract that it was not soaked up (a gastric lavage, uses of absorbent carbon, a purgative). Treatment is symptomatic with possible use of a-adrenomimetikov, for example noradrenaline.
The hemodialysis is inefficient because doksazozin almost completely contacts proteins of plasma.
Features of use.
There can be orthostatic hypotension, especially in an initiation of treatment. The patient should be warned about an opportunity such orthostatic hypotensions and to recommend to rise carefully after a sitting position or lying. on an initiation of treatment the patient has to avoid a situation when there can be an injury owing to dizziness or nausea. Especially it is important for people of advanced age and patients who accept other antihypertensives or diuretics.
Abnormal liver functions. At patients with an abnormal liver function delay of a metabolism of a doksazozin and therefore at its use care is necessary results.
Patients have to swallow a tablet of whole: not to chew it, to break or shatter.
Kamiren XL is not recommended to appoint to children as safety and efficiency of this drug in pediatric practice were not studied.
Pregnancy and lactation. Pregnant women should accept drug only in cases when the possible advantage for mother exceeds potential risk for a fruit. During treatment doksazoziny feeding by a breast is not recommended.
Influence on ability to steer the car and other mechanisms.
In an initiation of treatment and at increase of a dose arterial pressure with further dizziness dizziness can decrease considerably. Therefore during this period it is not recommended to steer the car or other mechanical means.
Interaction with other medicines. Doksazozin contacts proteins of a blood plasma. In the researches in vitro it is shown what doksazozin does not influence linkng of digoxin, Phenytoinum or indometacin with proteins of plasma. At patients who accepted doksazozin together with thiazide diuretics, furosemide, antagonists of beta receptors, non-steroidal anti-inflammatory drugs, antibiotics, peroral hypoglycemic means, uricosuric means or anticoagulants signs adverse interactions were not observed.
Conditions and periods of storage. To store at a temperature not above 25 °C. To store in the place, unavailable to children. A period of validity – 2 years.